See more : Century Iron and Steel Industrial Co.,Ltd. (9958.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Medexus Pharmaceuticals Inc. (MEDXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medexus Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Lakshmi Automatic Loom Works Limited (LXMIATO.BO) Income Statement Analysis – Financial Results
- Hwa Create Corporation (300045.SZ) Income Statement Analysis – Financial Results
- Catena Media plc (CTTMF) Income Statement Analysis – Financial Results
- Big Cypress Acquisition Corp. (BCYPW) Income Statement Analysis – Financial Results
- Aston Bay Holdings Ltd. (ATBHF) Income Statement Analysis – Financial Results
Medexus Pharmaceuticals Inc. (MEDXF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medexus.com
About Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M | 25.36M | 7.75M | 4.65M | 2.89M | 3.69M | 3.07M | 0.00 | 0.00 |
| Cost of Revenue | 53.54M | 48.06M | 38.77M | 37.66M | 22.99M | 10.38M | 3.85M | 2.08M | 998.43K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M | 14.98M | 3.90M | 2.57M | 1.89M | 3.69M | 3.07M | 0.00 | 0.00 |
| Gross Profit Ratio | 52.64% | 55.54% | 49.45% | 52.73% | 56.15% | 59.08% | 50.37% | 55.24% | 65.44% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 8.04M | 2.94M | 5.87M | 4.60M | 1.10M | 0.00 | 0.00 | 0.00 | 0.00 | 542.62K | 1.38M | 0.00 | 0.00 |
| General & Administrative | 27.86M | 36.86M | 34.52M | 19.28M | 11.77M | 5.64M | 1.58M | 2.15M | 2.72M | 1.21M | 2.02M | 149.56K | 136.14 |
| Selling & Marketing | 10.58M | 11.39M | 9.51M | 16.89M | 17.16M | 9.97M | 4.51M | 2.95M | 2.48M | 3.15M | 4.70M | 0.00 | 0.00 |
| SG&A | 38.44M | 48.25M | 44.03M | 36.17M | 28.93M | 15.62M | 6.09M | 5.10M | 5.20M | 4.36M | 6.72M | 149.56K | 136.14 |
| Other Expenses | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.72M | 51.55M | 50.30M | 41.27M | 30.48M | 15.66M | 6.10M | 5.12M | 5.28M | 4.90M | 8.10M | 149.56K | 136.14 |
| Cost & Expenses | 102.26M | 99.61M | 89.08M | 78.93M | 53.47M | 26.04M | 9.95M | 7.20M | 6.28M | 4.90M | 8.10M | 149.56K | 136.14 |
| Interest Income | 0.00 | 0.00 | 0.00 | 3.00K | 205.89K | 161.72K | 30.82K | 29.96K | 31.95K | 23.21K | 49.23K | 0.00 | 0.00 |
| Interest Expense | 13.36M | 13.61M | 12.22M | 9.82M | 6.44M | 2.90M | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.81M | 8.05M | 7.71M | 7.90M | 5.26M | 2.38M | 231.16K | 51.87K | 113.48K | 88.12K | 0.00 | 0.00 | 0.00 |
| EBITDA | 19.28M | 14.65M | 15.16M | -23.61M | 7.04M | 159.00K | -2.06M | -697.72K | -1.15M | -3.85M | -4.88M | -2.02M | -136.14 |
| EBITDA Ratio | 17.05% | 13.48% | -8.12% | 8.43% | 3.25% | 5.58% | -25.62% | -59.93% | -113.69% | -31.76% | -159.09% | 0.00% | 0.00% |
| Operating Income | 10.79M | 7.61M | -15.00M | -1.38M | -5.41M | -4.39M | -2.18M | -592.05K | -1.03M | -1.21M | -4.88M | -149.56K | -136.14 |
| Operating Income Ratio | 9.55% | 7.04% | -19.55% | -1.73% | -10.32% | -17.32% | -28.09% | -12.72% | -35.72% | -32.78% | -159.09% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.69M | -12.66M | 11.18M | -30.13M | 244.00K | -477.99K | -501.00K | -584.12K | -431.64K | 38.83K | -117.08K | 0.00 | 0.00 |
| Income Before Tax | 106.00K | -5.04M | -3.82M | -31.50M | -5.19M | -4.72M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
| Income Before Tax Ratio | 0.09% | -4.66% | -4.98% | -39.54% | -9.89% | -18.60% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
| Income Tax Expense | 320.00K | -6.26M | -941.00K | -3.24M | -790.44K | 166.29K | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
| Net Income | -214.00K | 1.22M | -2.88M | -28.26M | -4.40M | -4.88M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
| Net Income Ratio | -0.19% | 1.13% | -3.75% | -35.48% | -8.39% | -19.26% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
| EPS | -0.01 | 0.06 | -0.15 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
| EPS Diluted | -0.01 | 0.06 | -0.14 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 22.32M | 19.98M | 19.45M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
| Weighted Avg Shares Out (Dil) | 22.32M | 20.52M | 19.86M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
FDA Accepts for Review Treosulfan NDA Resubmission
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Medexus Pharmaceuticals Inc. (MEDXF) Q3 2024 Earnings Call Transcript
Medexus Announces Fiscal Q3 2024 Results
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Medexus Pharmaceuticals, Inc. (MEDXF) Q2 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports